BioLineRx firma acordo de desenvolvimento conjunto com GenFleet para intensificar o desenvolvimento do Motixafortide em adenocarcinoma ductal pancreático (PDAC), assessorada pela MSQ Ventures ...Middle East

NOVA YORK, 29 de junho de 2022 /PRNewswire/ -- A M.S.Q. Ventures ("MSQ") tem o prazer de anunciar que sua cliente BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX) firmou um acordo de desenvolvimento conjunto com a GenFleet Therapeutics, Inc., uma empresa biofarmacêutica com foco em...

Hence then, the article about biolinerx firma acordo de desenvolvimento conjunto com genfleet para intensificar o desenvolvimento do motixafortide em adenocarcinoma ductal pancreatico pdac assessorada pela msq ventures was published today ( Thursday 30/06/2022 - 01:08 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( BioLineRx firma acordo de desenvolvimento conjunto com GenFleet para intensificar o desenvolvimento do Motixafortide em adenocarcinoma ductal pancreático (PDAC), assessorada pela MSQ Ventures )

Also on site :

• Crews respond to large fire at Denny Hamlin's parents' house in Stanley: Sources
• Reported tornado rips roofs off multiple homes in central Illinois
• John Legend Celebrates 47th Birthday With Family Slime Outing in New York